Evidence map›Paper›PMID 37405633›Full record

ArticleDermatology and therapy2023

Hemoporfin-Mediated Photodynamic Therapy for Port-Wine Stains on Extremities.

Jie Kang, Jing-Jing Liu, Yu-Hong Fang, Yan-Yan Lin, Wei Gong, Huai-Yu Wang, Li-Hang Lin, Xue-Min Xiao

Open access · goldAbstract read
In one paragraph

Article in Dermatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Noninvasive Diagnosis Revealed a Strong Therapeutic Response and Skin Barrier Changes in Hemoporfin-Mediated Photodynamic Therapy for Port-Wine Stains.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2026
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jie Kang *Department of Dermatology, The Union Hospital-Fujian Medical University, Fuzhou, 350001, China.
Jing-Jing Liu *Department of Dermatology, The Union Hospital-Fujian Medical University, Fuzhou, 350001, China.
Yu-Hong FangKey Laboratory of OptoElectronic Science and Technology for Medicine of the Ministry of Education, College of Photonic and Electronic Engineering, Fujian Normal University, Fuzhou, 350007, China.
Yan-Yan LinDepartment of Dermatology, The Union Hospital-Fujian Medical University, Fuzhou, 350001, China.
Wei GongKey Laboratory of OptoElectronic Science and Technology for Medicine of the Ministry of Education, College of Photonic and Electronic Engineering, Fujian Normal University, Fuzhou, 350007, China.
Huai-Yu WangDepartment of Dermatology, The Union Hospital-Fujian Medical University, Fuzhou, 350001, China.
Li-Hang Lin *Department of Dermatology, The Union Hospital-Fujian Medical University, Fuzhou, 350001, China. 460879404@qq.com.
Xue-Min Xiao *Department of Dermatology, The Union Hospital-Fujian Medical University, Fuzhou, 350001, China. 258260101@qq.com.
Fujian Medical University · CNUnion Hospital · CNFujian Normal University · CN

Funding

Natural Science Foundation of Fujian Province 2020J011034
6 · The paper itself

Abstract

introductionPulsed dye laser (PDL) is currently considered to be the first-line treatment for port-wine stains (PWSs) on the extremities despite its less than satisfactory therapeutic efficacy. Hemoporfin-mediated photodynamic therapy (HMME-PDT) is a vascular-targeted therapy that has rarely been used to treat PWSs on the extremities. Here, we evaluate the clinical efficacy and safety of HMME-PDT for the treatment of PWSs on the extremities.

methodsClinical data and dermoscopic images of PWSs on the extremities were obtained from 65 patients who underwent HMME-PDT between February 2019 and December 2022. The clinical efficacy of HMME-PDT was analyzed by comparing the pre- and post-treatment images. The safety of HMME-PDT was evaluated through observation during the treatment period and post-treatment follow-up.

resultsThe efficacy rate of a single HMME-PDT session was 63.0% and that of two and three to six sessions was 86.7% and 91.3%, respectively. A positive correlation was found between therapeutic efficacy and the number of HMME-PDT sessions. The therapeutic efficacy of HMME-PDT was better on the proximal extremities than on other parts of the extremities (P = 0.038), and the efficacy of treating PWSs in each site was relatively improved with an increase of treatment time. The clinical efficacy of HMME-PDT differed across four PWS vascular patterns identified by dermoscopy (P = 0.019). However, there was no statistical difference in the therapeutic efficacy based on age, sex, type of PWS, and treatment history (P > 0.05), which may be partly attributed to the relatively small sample size or poor cooperation of infant patients. No obvious adverse reactions were observed during the follow-up period.

conclusionsHMME-PDT is a very safe and effective treatment for PWSs on the extremities. Multiple HMME-PDT treatments, lesions located in proximal limbs, and PWSs with type I and IV vascular patterns under dermoscopy were associated with higher efficacy of HMME-PDT. Dermoscopy may help predict the clinical efficacy of HMME-PDT. TRIAL REGISTRATION NO: 2020KJT085.

Indexed as

DermoscopyEfficacy analysisExtremitiesHematoporphyrin monomethyl etherPhotodynamic therapyPort-wine stains

Identifiers

PMID37405633
PMCPMC10366063
OpenAlexW4383186461

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.